A. Introduction
Drug resistance remains a major obstacle to cure of patients with acute leukemia. At the present time, most centers are reporting 90% complete remission rates in acute lymphatic leukemia (ALL) and 70%-80% complete remission rates in patients with acute nonlymphocytic leukemia (ANLL). However, 5-year disease-free survival rates are only 50% and 10%-15%, respectively, in these diseases. This is almost certainly due to the development of drug resistance even to the combination chemotherapy programs utilized to treat these diseases [1] .
In this paper, we review the mechanisms by which cells become resistant to methotrexate (MTX) and strategies to eradicate selectively leukemic cells that have acquired resistance to the drug.
B. Mechanisms of Acquired Resistance toMTX
Methotrexate has been an excellent model drug for the study of acquired drug resistance. There is little metabolism of the drug intracellularly (except for polyglutamylation discussed below), the mechanism of action of the drug is well known [inhibition of the enzyme dihydrofolate reductase (DHFR)], and at least three and possibly four different causes of acquired resistance to this drug have been observed. In addition very sensitive assays for DHFR enzyme activity have been developed, as well as mouse and human cDNA probes to detect gene amplification by sensitive "dotblot" techniques [2] .
When cell lines or transplanted experimental tumors are exposed to MTX, and resistant cells emerge, resistance usually is due to one of two causes. These are either an increase in DHFR or a decreased uptake of MTX. Less commonly observed have been resistant sublines with an altered DHFR (reviewed in [4]) or a decrease in MTX polyglutamate formation [5].
C. Increased Levels ofDHFR as a Cause of MTX Resistance Gene Amplification
Mouse, hamster, and human MTX-resistant cell lines have been described in recent years that have increased levels of DHFR (reviewed in [4] ). When these lines have been examined with appropriate cDNA probes, in all cases gene amplification has been found to accompany the increase in DHFR level, as well as a corresponding increase in the level of mRNA(s) for this enzyme.
We have recently described three MTXresistant sublines obtained from human cells propagated in continuous culture with an increased level of DHFR: a lymphoblastic leukemia line (CEM-CCRF) [6), a blast-cell line (K562) [7] , and a colon cancer cell line (HeT 8) (J. R. Bertino, unpublished observation). In all of these circum- The location of the unique DHFR gene in human cells has been reported to be on the :f:I: 5 chromosome [9]: of interest is that another Burkitt's human cell line resistant to MTX was found also to have a large HSR in the :j:j: 5 chromosome. However, another report of a KB human cell line also highly resistant to MTX contained an HSR in the :f:I: 10 chromosome [10] . In situ hybridization with a human cDNA probe has not yet been reported with any of these cell lines, so it is likely, although unproven, that these HSRs are the site of the amplified D HFR genes.
The human DHFR gene [7, 11, 12] has been reported to be very large (ca. 30 kb), similar to the size reported for the mouse gene [13] . The availability of both mouse and human cDNA probes has allowed us to demonstrate that there is a significant sequence diversity in the noncoding 3' end of the gene [7] . Chen et al. [12] and Masters et al. [11] have shown the presence in human DNAs of intronless DHFR genes or pseudogenes, which are nonfunctional [12] . Apparently these pseudogenes are not amplified in resistant cells; therefore they are easily missed in Southern blots from resistant-celliines [12] .
D. Gene Amplification as a General Mechanism of Resistance to Anticancer Drugs
Since the initial description of gene amplification as the mechanism by which mammalian cells become resistant to MTX, there have been several examples of gene amplification in cell lines resistant to other drugs (Table 2) . Thus, it has become evident that this is a mechanism by which cells can increase the production of a target enzyme or receptor, thus resulting in a drugresistant phenotype. Although not demonstrated conclusively as yet, the multi drugresistant phenotype (cross-resistance to several natural product anticancer agents when resistance is developed to only one) may also be due to gene amplification.
E. Gene Amplification in Patients with Leukemia Resistant to MTX
Although gene amplification is commonly observed in MTX-resistant sublines, it was important to demonstrate that this event occurs in patients developing resistance to this drug. It was expected that a low level of amplification would be sufficient to cause MTX resistance, since the dose of MTX that can be safely administered is limited by toxic effects on normal tissues. In the three patients reported (two leukemia [2, 3] and one small-cell lung car- Yes [17] Yes [18] Yes [19] (?) [20] (?) [21] Yes [22] (?) [23] vinblastine, anthracyclines)
cinoma [22] ), MTX resistance was found to be due to a low level of gene amplification (two-to fourfold). We are presently examining cells from additional leukemia patients thought to be clinically resistant to MTX in order to determine the frequency of this event as a mechanism of drug resistance to MTX. This will be of importance in regards to alternative treatment strategies (discussed below). We have found a rapid screening test for MTX resistance useful in determining whether resistance to MTX is present (PH] deoxyuridine incorporation into DNA in the absence and presence of MTX [23] ).
F. Altered DHFR as a Mechanism for MTX Resistance
In experimental sublines propagated in vitro or in vivo, alteration of DHFR as a cause of MTX resistance is less commonly observed than is impaired transport or elevated DHFR [24] . Several lines have been reported, however, with altered DHFR enzymes, and one gene has been cloned, and the cDNA sequenced [25] . Table 3 lists the lines that have been described, and the alteration of enzyme activity observed in regards to MTX affinity. It should be pointed out, however, that most of these lines contain normal as well as altered genes, and unless the two enzymes are separated completely, the MTX-binding data may be misleading. We have recently obtained a cell line with an altered DHFR from the HeT-8/R line that also contained an elevated normal DHFR. This line contains an 92 [32] 
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[27] 100 J. R. Bertino, unpublished observation 100,000 [29] enzyme with a relatively high V max as compared with the 3T6 MTX-resistant line. Thus we believe that a mutation at a different site(s) has occurred, as compared with the 3T6 mutation. Since it is believed that some 13 amino acids are involved in MTX binding to DHFR [26] , it is possible that mutations affecting any of these binding sites may produce an altered DHFR. These altered DHFR sublines have been extremely valuable as drug-selectable genes for DNA transfection studies, in particular the cDNA from the 3T6 cell line that has been inserted into plasmid and retrovirus vectors [25, 27, 28] .
G. MTX Resistance Due to Impaired Transport
Impaired MTX transport, like increased DHFR enzyme activity, has been noted to be a relatively common mechanism of resistance to this antifolate. In one study of drug resistance produced in vivo to cells in mice, impaired transport was as commonly noted as elevated DHFR as the cause of MTX resistance [24J. Little is known about the molecular nature of this resistance, which involves the carrier transport system present for the active transport for reduced folates (5-methyltetrahydrofolate, 5-formyl tetrahydrofolate). While this could also be an example of gene amplification, there was no cross-resistance to other antitumor agents noted when a CEM-CCRF transport mutant sub line was tested [33J. Thus far, the mammalian transport system for reduced folates and MTX has not been isolated or characterized, but these resistant sublines may allow an approach to this problem.
H. Eradication of Drug-Resistant Cells
Although the probability of drug resistance occurring to MTX may be decreased with the use of drug combinations, this possibility is limited for the treatment of many human malignancies because of the lack of useful agents for treatment. Also, the addition of alkylating agents to combination regimens may increase the probability of mutations leading to MTX resistance in surviving cells. Of great potential importance is the recent work of Schimke et aI., which suggests that gene amplification may be facilitated by agents that interrupt DNA synthesis early in S-phase [34J. Strategies to eradicate MTX-drug-resistant cells have been suggested by us as well as by others [35] [36] [37] [38] . A general approach involves the use of high specific activity PH] deoxyuridine in the presence of MTX and hypoxanthine and thymidine [35] . This combination would be lethal for MTX-resistant cells, since MTX would not block [3H] deoxyuridine incorporation into DNA, while in sensitive cells it would. This approach works in vitro, but will probably be impractical for in vivo use.
We have recently utilized a new inhibitor of DHFR, trimetrexate (TMQ) [39] , to treat MTX-resistant cells [33J. Trimetrexate or other folate antagonists that accumulate in cells to high levels and do not use the folate Table 4 . Effect of MTX and TMQ on the parenteral CCRF-CEM lymphoblastic leukemia cell line and two resistant sublines. The CCRF-CEM/R 1 line has a 20-fold increase in DHFR activity, while the R3 line has normal DHFR activity, but has a markedly impaired uptake of MTX [33] Cell line transport system may be effective agents against MTX-resistant cells with impaired transport or low levels of DHFR gene amplification [33, 34] . Table 4 indicates that trimetrexate is highly effective in a MTXtransport-resistant CCRF-CEM cell line (R3); and more effective than MTX in a CCRF-CEM cell line, with a 20-fold increase in DHFR (RI). In the 3T6 cell line resistant to MTX because of an altered DHFR, trimetrexate also has a markedly decreased affinity for the enzyme and thus would be of no value in the treatment of cells resistant by this mechanism [27J. We are currently attempting to look for inhibitors that would be effective against cells with an altered DHFR; selective inhibition may be possible in this circumstance.
We are testing these strategies by employing combinations of antifolates that presumably would limit the emergence of drug-resistant cells, e.g., concomitant MTX and trimetrexate treatment versus sequential uses of these agents. 
